

TECHNICAL DATA SHEET

CyFlow™ CD266 Purified Anti-Hu/Ms; Clone ITEM-4

REF AZ756227

For Research Use Only.

Not for use in diagnostic or therapeutic procedures.

Specifications

Antigen	CD266
Alternative Names	TWEAK R, Fn14, FN14, TNFRSF12A
Clone	ITEM-4
Clonality	monoclonal
Format	Purified
Host / Isotype	Mouse / IgG2b
Species Reactivity	Human Mouse
Negative Species Reactivity	—
Quantity [Concentration]	0.1 mg [1 mg/ml]
Immunogen	Human CD266-transfected P815 cells

Specificity

The mouse monoclonal antibody ITEM-4 recognizes CD266 (TWEAK R) antigen, a TNFR superfamily receptor for CD255 (TWEAK), a TNF-like weak inducer of apoptosis.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

Application

Based on published sources, this antibody is suitable for the following applications:

- Flow cytometry
- Western blot
- Immunohistochemistry (frozen sections)
- Functional assays

Storage Buffer

The reagent is provided in phosphate buffered saline (PBS) solution, pH $\approx$ 7.4, containing 0.1% (w/v) sodium azide.

Storage and Stability

Storage	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
Stability	Do not use after expiration date stamped on vial label.

Background Information

CD266 (TWEAK R, TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14), is a receptor for CD255 (TWEAK), the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.

References

- Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1; 170(1):341-8. < PMID: 12496418 >
- Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H: Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol. 2010 Aug 1; 185(3):1593-605. < PMID: 20610643 >

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

- Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. *Exp Ther Med*. 2011 Jan; 2(1):103-108. < PMID: 22977477 >
- Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A: Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. *PLoS One*. 2012; 7(10):e47440. < PMID: 23077618 >

The Safety Data Sheet for this product is available at www.sysmex-partec.com/services.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com